Change search
ReferencesLink to record
Permanent link

Direct link
The Effects of Exendin-4 Treatment on Graft Failure: An Animal Study Using a Novel Re-Vascularized Minimal Human Islet Transplant Model
Show others and affiliations
2015 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 10, no 3, e0121204Article in journal (Refereed) Published
Abstract [en]

Islet transplantation has become a viable clinical treatment, but is still compromised by long-term graft failure. Exendin-4, a glucagon-like peptide 1 receptor agonist, has in clinical studies been shown to improve insulin secretion in islet transplanted patients. However, little is known about the effect of exendin-4 on other metabolic parameters. We therefore aimed to determine what influence exendin-4 would have on revascularized minimal human islet grafts in a state of graft failure in terms of glucose metabolism, body weight, lipid levels and graft survival. Introducing the bilateral, subcapsular islet transplantation model, we first transplanted diabetic mice with a murine graft under the left kidney capsule sufficient to restore normoglycemia. After a convalescent period, we performed a second transplantation under the right kidney capsule with a minimal human islet graft and allowed for a second recovery. We then performed a left-sided nephrectomy, and immediately started treatment with exendin-4 with a low (20 mu g/kg/day) or high (200 mu g/kg/day) dose, or saline subcutaneously twice daily for 15 days. Blood was sampled, blood glucose and body weight monitored. The transplanted human islet grafts were collected at study end point and analyzed. We found that exendin-4 exerts its effect on failing human islet grafts in a bell-shaped dose-response curve. Both doses of exendin-4 equally and significantly reduced blood glucose. Glucagon-like peptide 1 (GLP-1), C-peptide and pro-insulin were conversely increased. In the course of the treatment, body weight and cholesterol levels were not affected. However, immunohistochemistry revealed an increase in beta cell nuclei count and reduced TUNEL staining only in the group treated with a low dose of exendin-4 compared to the high dose and control. Collectively, these results suggest that exendin-4 has a potential rescue effect on failing, revascularized human islets in terms of lowering blood glucose, maintaining beta cell numbers, and improving metabolic parameters during hyperglycemic stress.

Place, publisher, year, edition, pages
2015. Vol. 10, no 3, e0121204
National Category
Immunology in the medical area Medical and Health Sciences
URN: urn:nbn:se:uu:diva-252232DOI: 10.1371/journal.pone.0121204ISI: 000352083900111PubMedID: 25793295OAI: diva2:810028
Available from: 2015-05-06 Created: 2015-05-04 Last updated: 2015-11-30Bibliographically approved

Open Access in DiVA

fulltext(2978 kB)94 downloads
File information
File name FULLTEXT01.pdfFile size 2978 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Johansson, LarsKorsgren, Olle
By organisation
RadiologyClinical ImmunologyScience for Life Laboratory, SciLifeLab
In the same journal
Immunology in the medical areaMedical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 94 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 384 hits
ReferencesLink to record
Permanent link

Direct link